Diabetes related phenotypes and their influence on outcomes of patients with corona virus disease 2019 (COVID-19)
© 2023. BioMed Central Ltd., part of Springer Nature..
INTRODUCTION: Diabetes mellitus (DM) is associated with severe forms of COVID-19 but little is known about the diabetes-related phenotype considering pre-admission, on-admission and data covering the entire hospitalization period.
METHODS: We analyzed COVID-19 inpatients (n = 3327) aged 61.2(48.2-71.4) years attended from March to September 2020 in a public hospital.
RESULTS: DM group (n = 1218) differed from Non-DM group (n = 2109) by higher age, body mass index (BMI), systolic blood pressure and lower O2 saturation on admission. Gender, ethnicity and COVID-19-related symptoms were similar. Glucose and several markers of inflammation, tissue injury and organ dysfunction were higher among patients with diabetes: troponin, lactate dehydrogenase, creatine phosphokinase (CPK), C-reactive protein (CRP), lactate, brain natriuretic peptide, urea, creatinine, sodium, potassium but lower albumin levels. Hospital (12 × 11 days) and intensive care unit permanence (10 × 9 days) were similar but DM group needed more vasoactive, anticoagulant and anti-platelet drugs, oxygen therapy, endotracheal intubation and dialysis. Lethality was higher in patients with diabetes (39.3% × 30.7%) and increased with glucose levels and age, in male sex and with BMI < 30 kg/m2 in both groups (obesity paradox). It was lower with previous treatment with ACEi/BRA in both groups. Ethnicity and education level did not result in different outcomes between groups. Higher frequency of comorbidities (hypertension, cardiovascular/renal disease, stroke), of inflammatory (higher leucocyte number, RCP, LDH, troponin) and renal markers (urea, creatinine, potassium levels and lower sodium, magnesium) differentiated lethality risk between patients with and without diabetes.
CONCLUSIONS: Comorbidities, inflammatory markers and renal disfunction but not Covid-19-related symptoms, obesity, ethnicity and education level differentiated lethality risk between patients with and without diabetes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Diabetology & metabolic syndrome - 15(2023), 1 vom: 16. Okt., Seite 203 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Revised 21.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1186/s13098-023-01168-w |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363385282 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363385282 | ||
| 003 | DE-627 | ||
| 005 | 20231226093232.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13098-023-01168-w |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363385282 | ||
| 035 | |a (NLM)37845766 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Alves, Lais Isidoro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diabetes related phenotypes and their influence on outcomes of patients with corona virus disease 2019 (COVID-19) |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 21.11.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2023. BioMed Central Ltd., part of Springer Nature. | ||
| 520 | |a INTRODUCTION: Diabetes mellitus (DM) is associated with severe forms of COVID-19 but little is known about the diabetes-related phenotype considering pre-admission, on-admission and data covering the entire hospitalization period | ||
| 520 | |a METHODS: We analyzed COVID-19 inpatients (n = 3327) aged 61.2(48.2-71.4) years attended from March to September 2020 in a public hospital | ||
| 520 | |a RESULTS: DM group (n = 1218) differed from Non-DM group (n = 2109) by higher age, body mass index (BMI), systolic blood pressure and lower O2 saturation on admission. Gender, ethnicity and COVID-19-related symptoms were similar. Glucose and several markers of inflammation, tissue injury and organ dysfunction were higher among patients with diabetes: troponin, lactate dehydrogenase, creatine phosphokinase (CPK), C-reactive protein (CRP), lactate, brain natriuretic peptide, urea, creatinine, sodium, potassium but lower albumin levels. Hospital (12 × 11 days) and intensive care unit permanence (10 × 9 days) were similar but DM group needed more vasoactive, anticoagulant and anti-platelet drugs, oxygen therapy, endotracheal intubation and dialysis. Lethality was higher in patients with diabetes (39.3% × 30.7%) and increased with glucose levels and age, in male sex and with BMI < 30 kg/m2 in both groups (obesity paradox). It was lower with previous treatment with ACEi/BRA in both groups. Ethnicity and education level did not result in different outcomes between groups. Higher frequency of comorbidities (hypertension, cardiovascular/renal disease, stroke), of inflammatory (higher leucocyte number, RCP, LDH, troponin) and renal markers (urea, creatinine, potassium levels and lower sodium, magnesium) differentiated lethality risk between patients with and without diabetes | ||
| 520 | |a CONCLUSIONS: Comorbidities, inflammatory markers and renal disfunction but not Covid-19-related symptoms, obesity, ethnicity and education level differentiated lethality risk between patients with and without diabetes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Clinical data | |
| 650 | 4 | |a Diabetes | |
| 650 | 4 | |a Laboratory data | |
| 650 | 4 | |a Outcome | |
| 700 | 1 | |a Bosco, Adriana Aparecida |e verfasserin |4 aut | |
| 700 | 1 | |a Rosa, Adriana Aparecida |e verfasserin |4 aut | |
| 700 | 1 | |a Correia, Marcia Regina Soares |e verfasserin |4 aut | |
| 700 | 1 | |a Matioli, Sergio Russo |e verfasserin |4 aut | |
| 700 | 1 | |a da Silva, Maria Elizabeth Rossi |e verfasserin |4 aut | |
| 700 | 0 | |a HCFMUSP COVID-19 Study Group |e verfasserin |4 aut | |
| 700 | 1 | |a Barros-Filho, Tarcisio E P |e investigator |4 oth | |
| 700 | 1 | |a Utiyama, Edivaldo M |e investigator |4 oth | |
| 700 | 1 | |a Segurado, Aluisio C |e investigator |4 oth | |
| 700 | 1 | |a Perondi, Beatriz |e investigator |4 oth | |
| 700 | 1 | |a Montal, Amanda C |e investigator |4 oth | |
| 700 | 1 | |a Harima, Leila |e investigator |4 oth | |
| 700 | 1 | |a Fusco, Solange R G |e investigator |4 oth | |
| 700 | 1 | |a Silva, Marjorie F |e investigator |4 oth | |
| 700 | 1 | |a Rocha, Marcelo C |e investigator |4 oth | |
| 700 | 1 | |a Rios, Izabel Cristina |e investigator |4 oth | |
| 700 | 1 | |a Kawano, Fabiane Yumi Ogihara |e investigator |4 oth | |
| 700 | 1 | |a Jesus, Maria Amélia de |e investigator |4 oth | |
| 700 | 1 | |a Kallas, Esper |e investigator |4 oth | |
| 700 | 1 | |a Francisco, Maria Cristina Peres Braido |e investigator |4 oth | |
| 700 | 1 | |a Carmo, Carolina Mendes do |e investigator |4 oth | |
| 700 | 1 | |a Tanaka, Clarice |e investigator |4 oth | |
| 700 | 1 | |a Oliveira, Maura Salaroli |e investigator |4 oth | |
| 700 | 1 | |a Guimarães, Thaís |e investigator |4 oth | |
| 700 | 1 | |a Lázari, Carolina Dos Santos |e investigator |4 oth | |
| 700 | 1 | |a Magri, Marcello M C |e investigator |4 oth | |
| 700 | 1 | |a Marchini, Julio F M |e investigator |4 oth | |
| 700 | 1 | |a Duarte, Alberto José da Silva |e investigator |4 oth | |
| 700 | 1 | |a Sabino, Ester C |e investigator |4 oth | |
| 700 | 1 | |a Costa, Silvia Figueiredo |e investigator |4 oth | |
| 700 | 1 | |a Morais, Anna Miethke |e investigator |4 oth | |
| 700 | 1 | |a Souza, Heraldo Possolo de |e investigator |4 oth | |
| 700 | 1 | |a Carvalho, Carlos Roberto Ribeiro |e investigator |4 oth | |
| 700 | 1 | |a Ferreira, Juliana Carvalho |e investigator |4 oth | |
| 700 | 1 | |a Levin, Anna Sara Shafferman |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetology & metabolic syndrome |d 2009 |g 15(2023), 1 vom: 16. Okt., Seite 203 |w (DE-627)NLM192019317 |x 1758-5996 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:1 |g day:16 |g month:10 |g pages:203 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s13098-023-01168-w |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 1 |b 16 |c 10 |h 203 | ||